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Neuropsychiatric systemic lupus erythematosus (NPSLE) is a serious complication in 
SLE. Although the mechanism of NPSLE remains unclear, cytokine and chemokines are 
considered to be involved in their pathogenesis. Here we used Bio-Plex Pro assays to 
examine 27 types of cytokines and chemokines in the cerebrospinal fluid (CSF) of 32 
NPSLE patients. We used the CSF of 20 patients with multiple sclerosis (MS) and 22 
patients with neuromyelitis optica (NMO) as a disease control group. Fourteen of 27 
cytokines/chemokines were significantly higher in the NPSLE patients compared to the 
MS/NMO patients. We could identify six “minimum predictive markers” by using a 
weighted-voting algorithm that could distinguish NPSLE from MS and NMO: 
interleukin (IL)-17, IL-2, interferon (IFN)-γ, IL-5, basic fibroblast growth factor 
(FGF)-basic and IL-15. The determination of various types of CSF cytokine profiles 





Neuropsychiatric systemic lupus erythematosus (NPSLE) syndromes involve both the 
central and peripheral nervous systems. Despite advances in the understanding of the 
immunopathogenic and clinical aspects of SLE, NPSLE remains a diagnostic and 
therapeutic challenge [1]. Cytokines and chemokines are considered biomarkers and 
therapeutic targets in NPSLE. Of note, abnormalities in cerebrospinal fluid (CSF) have 
been reported in patients with NPSLE. Increased levels of proinflammatory cytokines 
and chemokines have been reported in the CSF of patients with NPSLE, including 
cytokines such as interleukin (IL)-6, IL-8, IL-10, tumor necrosis factor-alpha (TNF-α), 
interferon-gamma (IFN-γ), C-C motif ligand (CCL)2/monocyte chemoattractant 
protein-1 (MCP-1) and C-X-C motif ligand (CXCL) 10/inducible protein-10 (IP-10) [2, 
3]. Among these, CSF IL-6 is major cytokine for the diagnosis of NPSLE. IL-6 is a 
proinflammatory cytokine secreted by immune cells and activated astrocytes, with a 
wide variety of functions. The sensitivity and specificity of the diagnosis of lupus 
psychosis were 87.5% and 92.3%, respectively, at the cut-off value of 4.3 pg/mL [4]. 
Multiple sclerosis (MS) and neuromyelitis optica (NMO) are chronic 
autoimmune inflammatory diseases affecting the central nervous system (CNS). 
Disruption of the blood-brain barrier (BBB) is a known mechanism of the disease 
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process in these two CNS diseases. MS and NMO are also considered T cell-mediated 
autoimmune diseases, and both the Th1/Th2 balance and Th17 cells play an important 
role in the pathogenesis [5]. Elevated CSF IL-6 and IL-8 levels in NMO patients have 
also been reported [6]. CSF IL-6 and IL-8 levels are significantly higher in patients with 
NMO than in patients with MS [6]. Similar cytokines/chemokines have been evaluated 
in NPSLE, MS and NMO but the therapeutic strategy and management are quite 
different among these three diseases. 
In this study we evaluated multiple cytokines, chemokines and growth factors in 
NPSLE compared to MS and NMO as disease controls. We found a specific 
combination of cytokines, chemokines and growth factors in NPSLE that can be 
distinguished from the profiles of the other two diseases. This analysis might help 
clarify the mechanism of NPSLE caused by inflammation and may provide an 
important resource for pharmaceutical developments. 
 
2. Methods 
2.1. Study design and patients 
We studied 32 patients who were admitted to Nagasaki University Hospital in a 7-year 
period from 2006 through 2013 and fulfilled at least four of the 11 revised criteria of the 
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American College of Rheumatology (ACR) for the classification of SLE [7]; they were 
all diagnosed with NPSLE by rheumatologists and psychiatrists. Neuropsychiatric 
manifestations showing psychiatric symptoms such as mood disorder, anxiety disorder, 
psychosis, acute confusional state, or cognitive dysfunction were evaluated by a 
psychiatrist and classified according to the ACR nomenclature and case definitions for 
NPSLE [8]. 
All information about clinical symptoms and laboratory data were reviewed 
retrospectively using the patients’ medical records. The patients’ age, gender, clinical 
events, results of serum laboratory tests, the CSF analysis, brain magnetic resonance 
imaging (MRI), and single photon emission computed tomography (SPECT) and their 
diagnoses and treatment were all analyzed. 
As disease controls, we used samples from 20 relapsing remitting MS (RRMS) 
patients, samples from 22 NMO patients, 11 normal pressure hydrocephalus (NPH) 
patients, and 16 viral meningitis (VM) patients from the Department of Clinical 
Neuroscience and Neurology, Nagasaki University Hospital. For the diagnosis of NMO, 
we defined NMO spectrum disorder (NMOSD) based on the revised NMO criteria [9]. 
All of the NMO patients were positive for anti-AQP4 antibodies in sera. CSF of NPH 
patients were used for non-autoimmune, non-inflammatory neurological controls and 
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VM patients were used for positive controls. The protocol was approved by the 
Institutional Review Board of the Nagasaki University Hospital. 
 
2.2. Multiplex cytokine bead assay 
We performed a multiplex cytokine bead assay using undiluted CSF supernatants and 
the Bio-Plex Pro Human Cytokine Group I 27-Plex Panel analyzed with a Bio-Plex® 
MAGPIX™ Multiplex Reader (Bio-Rad, Hercules, CA) according to the manufacturer’s 
instructions. CSF samples were centrifuged within 30 min at 1500 rpm at 4°C for 5 min, 
and the liquid phase of the CSF was stored at −80°C until use. The levels of 27 
cytokines/chemokines and growth factors in the liquid phase of the CSF, namely, IL-1β, 
IL-1 receptor antagonist (IL-1ra), IL-2, IL-4, IL-5, IL-6, IL-7, CXCL8/IL-8, IL-9, 
IL-10, IL-12 (p70), IL-13, IL-15, IL-17A, basic fibroblast growth factor (FGF)-basic, 
CCL11/eotaxin, granulocyte colony stimulating factor (G-CSF), 
granulocyte-macrophage colony stimulating factor (GM-CSF), IFN-γ, IP-10, 
CCL2/MCP-1, CCL3/macrophage inflammatory protein (MIP)-1α, CCL4/MIP-1β, 
platelet-derived growth factor (PDGF)-BB, CCL5/regulated on activation, normal T cell 
expressed and secreted (RANTES), TNF-α, and vascular endothelial growth factor 
(VEGF) were measured as described [10, 11]. 
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The cytokines/chemokines/growth factors concentrations were calculated based on 
the respective standard curve for each cytokine/chemokine/growth factor concentration 
of the standards assayed in the same manner as the CSF samples. The detection limit for 
each molecule was determined by the recovery of the corresponding standard, and the 
lowest values with more than 70% recovery were set as the lower detection limits. All 
samples were analyzed in duplicate. 
 
2.3. Construction of diagnostic systems 
Next, we selected which of the 27 cytokines/chemokines/growth factors were useful 
markers for distinguishing NPSLE from MS and NMO. The weighted-voting (WV) 
algorithm was used as described [12, 13]. The ranking of the 27 cytokines/chemokines 
for this algorithm was based on the signal-to-noise ratio (SNR). For each marker set of 
27 cytokines/chemokines/growth factors based on the absolute value of the SNR, we 
calculated the sensitivity, specificity, accuracy, positive predictive value, negative 
predictive value, and Matthews correlation coefficient (MCC). The MCC is used as a 
measure of the quality of binary (two-class) classifications. We defined the “distinction 
set” as a set that had a minimum number of markers with higher MCCs. 
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In the WV algorithm, each marker belonging to a predictor set is assigned a vote 
value, and prediction is based on the relative vote value in NPSLE and in MS and 
NMO. The vote value of marker ‘a,’ Va, and the weight of marker ‘a,’ Wa, are calculated 
by the following two formulas: 
 
Here, Xa is the expression level of each marker a in a CSF sample. X̄na is the mean 
expression level of each marker ‘a’ in NPSLE in the learning set. X̄oa represents the 
mean expression level in the other diseases (i.e., MS and NMO). Sna is the standard 
deviation in NPSLE, and Soa represents the standard deviation in the others. The SNR 
used for ranking the markers is the absolute value of Wa; the diagnostic markers were 
selected in descending order of SNR. We selected 'i' pieces of markers, in the order of 
the absolute number of SNR, and we defined the prediction strength (PS) value of the i 




In the case of missing values, the vote of the gene is assigned as 0. PS is defined in 
which positive and negative PS indicates the prediction of others and NPSLE, 
respectively. 
 
2.4. Statistical analysis 
We used a t-test and the nonparametric Wilcoxon rank sum test for the inter-group 
comparisons of multiple variables. The Spearman rank correlation coefficient was used 
for the analyses of correlations between cytokines, chemokines, and growth factors in 
the patients with NPSLE, MS and NMO. All of the statistical analyses were performed 
using JMP® Pro10 (SAS Institute, Cary, NC, USA) and R Statistical Software 




3.1. Demographic and disease-related variables 
Supplementary Table 1 shows the demographic and disease-related characteristics of the 
32 NPSLE patients at examination. Thirty-one of the 32 patients (96.9%) were females. 
The median age at the onset of NPSLE was 34.9 yrs, ranging from 15 to 50 yrs. The 
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median duration from SLE onset to first neuropsychiatric event was 8.7 yrs. The median 
SELENA-SLEDAI score at the disease onset of NPSLE was 13.3. The median levels of 
anti-ds-DNA antibodies (U/mL), C3 (mg/dL) and C4 (mg/dL) were 20.2, 86.3 and 19.4, 
respectively. The median level of CSF IgG index was 0.61. Seven (21.9%) of the 
NPSLE patients also fulfilled the criteria for the antiphospholipid syndrome. Eight 
(25.0%) of the patients had anti-ribosomal P antibodies, and 17 (53.1%) patients had 
abnormal MRI findings. 
A total of 39 neuropsychiatric manifestations were observed in the 32 NPSLE 
patients. Nine of the 19 ACR Ad Hoc Committee classifications of NPSLE 
manifestations [2] were identified in this study (Suppl. Table 2). Nine of the 32 (28.1%) 
patients presented more than one NPSLE manifestation. Most of the NPSLE 
manifestations (97.4%) were in the CNS. The most frequent manifestation was 
headache (35.9%), followed by psychosis (25.6%) and mood disorder (12.8%). 
 
3.2. Comparison of cytokine/chemokine/growth factor levels 
We analyzed 32 NPSLE patients, 20 RRMS patients, samples from 22 patients with 
NMO, 11 NPH patients and 16 VM patients. The representative results are shown in 
Supplementary Figure 1. Although some of the cytokine and chemokine levels of the 
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VM patients were extremely high compared to the other groups, we did not observe any 
significant differences among the NPSLE, MS and NMO groups. We therefore referred 
to a previous report [14] and compared the results among only the present NPSLE, MS 
and NMO groups. Since there was no significant difference between the MS and NMO 
groups (Fig. 1), we speculated that it is problematic to distinguish MS and NMO, and 
we thus compared NPSLE and the “others” (i.e., the combined group of MS and NMO 
patients). 
Fourteen of the 27 cytokines/chemokines/growth factors were significantly higher 
in the NPSLE group compared to the others (Table 1). CSF IL-6 and IL-8 levels, which 
had been reported to be increased in NPSLE and NMO, were not significantly different 
between the present NPSLE group and the others. Only the CSF level of IL-1β was 
lower in the NPSLE group compared to the others. 
 
3.3. Ranking of the cytokines/chemokines/growth factors for diagnosing NPSLE 
Our ranking of the cytokines/chemokines/growth factors for diagnosing NPSLE 
determined by the weighted-voting algorithm showed that the combination of IL-17, 
IL-2, IFN-γ, IL-5, FGF-basic and IL-15 had the highest MCC (88.99%). According to 
this method, the accuracy of discriminating a responder from a non-responder was 
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94.59% (Table 2). The WV values (va) of each of these six markers and the PS value 
were obtained by the formulas shown in Supplementary Table 3; Xa is the expression 
level of each marker ‘a’ in a CSF sample. 
 
4. Discussion 
NPSLE is still diagnosed based on a combination of clinical observations, laboratory 
tests and imaging techniques, because there are no specific markers for NPSLE. 
Multiple cytokines and chemokines have been implicated in the pathophysiology of 
NPSLE. Previous studies obtained evidence of the intrathecal production of IL-6 [3, 4] 
and other cytokines including IL-8 [3, 15], IL-10 [16], TNF-α [16] and IFN-γ [17] in 
patients with NPSLE. Cytokines associated with NPSLE are produced by neuronal and 
glial cells, probably in response to autoantibodies within the intrathecal space. 
MS and NMO, chronic autoimmune inflammatory diseases affecting the CNS, 
are sometimes difficult to distinguish from NPSLE. An overlap diagnosis often referred 
to as lupoid sclerosis has been described [18]. In SLE, MS and NMO, the BBB is 
pivotal. There is evidence implicating BBB damage as an important component in the 
development of NPSLE, MS and NMO, occurring through damage to the barrier’s 
integrity by environmental triggers such as cytokines, chemokines and growth factors. 
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For example, the stimulation of human brain microvessel endothelial cells 
(HBMECs) with cytokines such as IL-1β, IL-8, TNF- α, and IFN-γ is known to induce 
increased permeability of the monolayers [19, 20]. Additionally, CSF from NPSLE 
patients with IL-6 and IL-8 was correlated with MMP-9 levels, and the latter is 
associated with degradation of the BBB extracellular matrix [21]. In both an in vitro 
investigation and in CCR2−/− mice, CCL2 signaling appeared to play a role in BBB 
disruption [22, 23]. 
We found that 14 of the 27 CSF cytokines/chemokines/growth factors used in 
the present study were significantly higher in the NPSLE group compared to the others 
(Table 1). In addition, we measured the serum markers of NPSLE, MS and NMO at 
nearly the same time that the lumbar puncture was performed. We found that serum 
IL-15 and IFN-γ were significantly increased in the non-NPSLE patients compared to 
the NPSLE patients (Suppl. Table 4). It is interesting that these results were the inverse 
of the CSF cytokines’ results, and these results might indicate that BBB disruption is 
much stronger in NPSLE compared to non-NPSLE. 
CSF IL-6 is a major cytokine for the diagnosis of NPSLE because of its 
sensitivity and specificity in certain conditions [4]. Elevated CSF IL-6 levels in NPSLE 
and NMO patients have been reported [3, 6]. However, our present findings showed that 
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there was no significant difference in the CSF IL-6 levels among the NPSLE, MS and 
NMO patients (data not shown). We speculate that CSF IL-6 is involved to some extent 
in the pathogenic mechanism of all of these autoimmune neurological diseases, and thus 
CSF IL-6 was not a marker that could be used to distinguish them. 
Our study shows for the first time identified predictive markers in the CSF of 
NPSLE patients compared to MS and NMO patients. Among them, IL-17, IL-2, IL-5, 
FGF-basic and IL-15 have not been well documented in NPSLE. There has been an 
increasing focus on the role of Th17, which might be a promising therapeutic target for 
SLE. CD3+CD4(−)CD8(−) (double-negative) T cells are an important source of IL-17 
in SLE. IL-17 produced by double-negative and CD4 T cells participates in the 
pathogenesis of SLE [24]. IL-17 promotes the production of IL-6 [25] and other 
inflammatory mediators by endothelial cells, fibroblasts, macrophages and astrocytes 
[26] . 
IL-2, a cytokine with multifaceted effects, is important for immune cell 
activation and peripheral tolerance. The therapeutic efficacy of IL-2 in SLE has been 
suggested [27, 28]. In another study, no association with IL-2 was found in NPSLE 
patients who had neurological symptoms without evidence of a neurological disease 
[29]. However, our patients’ backgrounds are different from those of the patients in that 
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study; we compared NPSLE patients with those with other autoimmune neurological 
disorders. The meaning of elevated IL-2 in NPSLE is requires further investigation. 
As with IL-2, IL-15 can expand T-cell populations, and IL-15-deficient mice 
have greatly reduced numbers of lymphocytes [30]. Moreover, IL-15 can promote 
excessive antibody production in B cells [31]. Increased levels of serum IL-15 has also 
been observed in patients with SLE, and the IL-2R are correlated with markers that are 
potential targets of IL-15 [32]. 
The possible role of IL-5 in the pathogenesis of lupus has not been extensively 
evaluated. Several studies suggested that abnormally high levels of IL-5 may have a role 
in the abnormal expansion of auto-reactive B-1 cells and the subsequent suppression of 
autoimmune disease [33]. Additionally, elevated IL-5 mRNA has been reported in 
cutaneous lupus erythematosus [34]. The authors of those studies suggested that IL-5, 
produced by the Th2 subset of CD4+ T cells may contribute the development of 
autoimmunity in lupus. However, the potential relevance of these results to NPSLE is 
unclear. 
FGF-basic is a potent angiogenic factor whose activity is involved in endothelial 
cell and fibroblast survival, proliferation, migration, and tube formation, together with 
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VEGF [35]. An increased FGF-basic level was reported in lupus and tended to be 
correlated with disease activity [36]. 
There has been no thorough comparison of the CSF of NPSLE, MS and NMO 
patients, to the best of our knowledge. Here, we found that NPSLE patients showed 
significantly higher levels of cytokines, chemokines and growth factors compared to 
MS and NMO patients. Among these factors, IL-17, IL-15, IL-9, IL-5, IL-12 p70, IL-7, 
FGF-basic, eotaxin, IL-13, GM-CSF and VEGF had not been observed in the CSF of 
NPSLE patients. In the present examination, we were able to detect cytokines, 
chemokines and growth factors with the Bio-plex assay, even if they were present in 
very small amounts. Since almost all of the above markers had already been shown 
elsewhere to be increased in MS or NMO, it would be difficult to distinguish MS or 
NMO from NPSLE using the above markers. We therefore devised a numerical 
prediction scoring system that clearly separated the NPSLE patients from the other 
patients. We identified six “minimum predictive markers” — IL-17, IL-2, IFN-γ, IL-5, 
FGF-basic and IL-15 — by a weighted-voting algorithm that showed the highest MCC 
and predicted the test set with 94.59% accuracy. 
These predictive markers seem not to be correlated with each other; however 
they certainly involve Th1, Th2 and Th17 cells. This may indicate that these six markers 
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contribute more strongly to induce both pro-inflammatory and antibody-mediated 
neuronal and glial cells’ destruction in NPSLE compared to MS and NMO, and we 
suspect that they are essential for the pathogenesis of NPSLE. 
Focusing on other markers is also important. We found that the correlations of 
pairs of cytokines/chemokines/growth factors showed different patterns in NPSLE, MS 
and NMO. The correlation coefficients of the cytokines/chemokines were the most 
significant: PDGF-BB, MIP-1a, MIP-1b and RANTES in NPSLE, IL-1b and IL-1ra in 
MS, and IL-12(p70) and VEGF in NMO (Suppl. Fig. 2). Examinations of each single 
marker may be meaningless, because each marker operates together with one or more 
other markers in a rather complex system. These results indicate that the downstream 
pathway of Th1/Th2/Th17-related mediators differs among NPSLE, MS and NMO. 
Various markers are known to be involved in the pathology of NPSLE; however, 
no predictive markers for detecting NPSLE were reported prior to the present study. 
Here, we were able to identify six minimum predictive markers (IL-17, IL-2, IFN-γ, 
IL-5, FGF-basic and IL-15), by using a weighted-voting algorithm with the highest 
MCC that could predict NPSLE from other autoimmune neurological diseases with 
94.59% accuracy. We examined the correlations of cytokines/chemokines/growth 
factors in NPSLE, MS and NMO, and we found that many 
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cytokines/chemokines/growth factors were operating together in NPSLE compared to 
MS and NMO. The determination of various types of CSF cytokine profiles may 
contribute to the diagnosis of NPSLE and may help elucidate the mechanisms 
underlying this disease. 
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Supplementary Fig. 1. Representative expressions of IL-17, IL-2, IFN-γ, 
IL-5, FGF-basic and IL-15 in the patients with NPH, VM, NPSLE, MS or 
NMO. 
 
Supplementary Fig. 2. Heat-maps of nearest-neighbor correlations of 
cytokines, chemokines and growth factors in patients with NPSLE, MS 
and NMO. Among the cytokines, chemokines and growth factors 
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Table 1. Comparison of each marker in cerebrospinal fluid among NPSLE, MS and NMO. P-value of each disease vs. the other two is 
shown. 
 
Marker NPSLE vs. Others MS vs. Others NMO vs. Others Up/down of NPSLE vs. Others 
IL-17 7.1981E-13 0.005200983 6.06716E-08 up 
IL-2 1.79273E-09 0.000183297 3.05064E-07 up 
FGF-basic 3.17974E-08 0.048298753 0.000240424 up 
IL-5 1.73358E-07 0.001280693 0.000544469 up 
IL-15 2.32436E-07 0.003814834 0.000574384 up 
IL-9 3.0018E-07 0.000287076 0.041266563 up 
IFN-γ 1.15444E-06 1.34983E-05 0.000209175 up 
IL-12(p70) 2.06811E-06 0.016465613 0.001083612 up 
IL-10 1.28056E-05 0.001591964 0.00011084 up 
IL-7 2.57896E-05 0.01531653 0.004787909 up 
GM-CSF 0.000174931 0.822364295 4.22879E-05 up 
IL-13 0.000194842 0.023994687 0.022546951 up 
TNF-α 0.000984547 0.002751192 0.012722463 up 
Eotaxin 0.002694469 0.005361471 0.00337151 up 
IL-8 0.923993657 0.003915445 0.106276224 up 
IL-6 0.974937316 0.014641205 0.153928475 up 
Table 2. Ranking of the cytokines/chemokines for the diagnosis of NPSLE determined by a weighted-voting algorithm with the 
highest Matthews correlation coefficient 
 






IL-17 29 3 38 4 90.63% 90.48% 90.54% 87.88% 92.68% 80.83% 
IL-2 28 4 39 3 87.50% 92.86% 90.54% 90.32% 90.70% 80.69% 
IFN-γ 28 4 41 1 87.50% 97.62% 93.24% 96.55% 91.11% 86.38% 
IL-5 28 4 41 1 87.50% 97.62% 93.24% 96.55% 91.11% 86.38% 
FGF-basic 28 4 40 2 87.50% 95.24% 91.89% 93.33% 90.91% 83.49% 
IL-15 30 2 40 2 93.75% 95.24% 94.59% 93.75% 95.24% 88.99% 
IL-8 7 25 39 3 21.88% 92.86% 62.16% 70.00% 60.94% 21.35%  
IL-6 7 25 39 3 21.88% 92.86% 62.16% 70.00% 60.94% 21.35%  
TP: true positives (predicted positive, actual positive); FN: false negatives (predicted negative, actual positive); TN: true negatives (predicted 
negative, actual negative); FP: false positives (predicted positive,actual negative). MCC: Matthews correlation coefficient. 
 
Supplementary Table 1. Baseline variables of the 32 neuropsychiatric systemic lupus 
erythematosus (NPSLE) patients 
  
Gender (female %) 96.9% 
Age, median (range), yrs 34.9 (15–50) 
SLE duration, median (range), yrs 8.7 (0.1–33)  
SELENA-SLEDAI score, median (range) 13.3 (2–28) 
anti-ds DNA antibodies, median (range), U/mL 20.2 (0.4–274) 
C3, median (range),mg/dL 86.3 (31.1–143) 
C4, median (range), mg/dL 19.4 (2.1–50.3) 
CSF IgG index 0.61 (0.47–0.87) 
% of APS patients 7/32 (21.9%) 
% of anti-ribosomal P antibody 8/32 (25.0%) 
% of abnormal MRI findings 17/32 (53.1%) 
 
SELENA-SLEDAI: The NPSLE patients’ Safety of Estrogens in Lupus Erythematosus National 
Assessment–Systemic Lupus Erythematosus Disease Activity Index, CSF: cerebrospinal fluid, 
APS: antiphospholipid syndrome. 
Supplementary Table 2. Neuropsychiatric manifestations of the 32 NPSLE patients 
Central nervous system 
Headache, n (%) 14 (35.9)* 
Psychosis, n (%) 10 (25.6)* 
Mood disorder, n (%) 5 (12.8)* 
Cognitive dysfunction, n (%) 2 (5.1) 
Acute confusional state, n (%) 2 (5.1)* 
Cerebrovascular disease, n (%) 2 (5.1)* 
Seizure disorders, n (%) 2 (5.1)* 
Cranial neuropathy, n (%) 1 (2.6)* 
Peripheral nervous system 
Mononeuropathy, single/multiplex, n (%) 1 (2.6)* 






















Supplementary Table 3. Formulas for determining the prediction strength value using 
six markers 
Marker Formula of weight vote value 
IL-17  VIL-17 = [Xa − (19.33+10.31)/2] × (−1.07) 
IL-2 VIL-2 = [Xa − (6.70+3.10)/2] × (−0.99) 
IFN-γ  VIFN-γ= [Xa − (25.73+12.29)/2] × (−0.80) 
IL-5 VIL-5 = [Xa − (0.82+0.37)/2] × (−0.73) 
FGF-basic VFGF-basic= [Xa − (16.24+10.19)/2] × (−0.72) 






The weighted vote value (va) of each of the six markers was obtained by the 





















Supplementary Table 4. Comparison of each marker in serum among 
NPSLE and other autoimmune neurological diseases (non-NPSLE). 
P-value of NPSLE vs. non-NPSLE  
Marker  NPSLE non-NPSLE p-value 
PDGF-BB 3019±326 3507±334 0.3015 
IL-1β 1.72±0.41 2.50±0.42 0.2035 
IL-1ra 93.5±38.3 202.1±39.2 0.0672 
IL-2 1.46±0.83 3.56±0.85 0.0963 
IL-4 4.66±0.42 5.91±0.43 0.0515 
IL-5 0.56±0.06 0.66±0.06 0.3030 
IL-6 15.4±3.19 20.5±3.27 0.2659 
IL-7 8.38±1.02 8.32±1.04 0.9694 
IL-8 43.6±17.8 31.4±18.3 0.6296 
IL-9 154.6±34.8 156.8±35.7 0.9647 
IL-10 2.94±0.58 4.65±0.59 0.0511 
IL-12(p70) 12.4±1.82 16.0±1.87 0.1811 
IL-13 8.36±2.23 13.2±2.29 0.1493 
IL-15 0.00±0.89 3.13±0.92 0.0275* 
IL-17 55.8±5.30 61.8±5.43 0.4374 
Eotain 29.4±5.00 44.0±5.12 0.0547 
FGF-basic 8.26±1.02 9.73±1.05 0.3250 
G-CSF 6.83±0.76 8.33±0.81 0.2040 
GM-CSF 31.4±7.53 14.3±7.72 0.1180 
IFN-γ 41.5±5.57 62.5±5.70 0.0164* 
IP-10 979.7±198.3 612.5±203.2 0.2017 
MCP-1 36.5±6.28 26.9±6.43 0.2891 
MIP-1a 7.09±1.51 3.76±1.55 0.1306 
MIP-1b 90.9±10.5 87.6±10.8 0.8247 
RANTES 8076±2008 9526±2058 0.6225 
TNF-α 27.6±4.56 40.7±4.67 0.0618 
VEGF 164.2±29.8 228.2±30.5 0.1484 
*Significant differences between the groups (p<0.05) 
